1887

Abstract

subsp. Typhi ( Typhi) Vi antigen capsular polysaccharide (Vi-CPS) is a licensed vaccine against typhoid fever. As there is no animal model for Typhi fever to evaluate the protective efficacy of the Vi-CPS vaccine, a serum bactericidal assay (SBA) is the recommended ‘gold standard’ to evaluate its potency. Vi-CPS was extracted from Typhi Ty6S (CSBPI-B191) using a modified Gotschlich method. Purified Vi-CPS (50 µg) was injected intramuscularly into three groups of five rabbits; group 2 received an additional booster dose of 50 µg Vi-CPS on day 15 and group 3 received two additional boosters on days 15 and 30. The sera obtained from each group were tested by SBA on days 0, 15, 30 and 45. The anti-Vi-CPS titres for groups 1, 2 and 3 on days 15, 30 and 45 were 4, 16 and 16; 4, 32 and 32; and 16, 64 and 64, respectively. Thus, Vi-CPS was shown to be a potent immunogen, as even one dose could induce an efficient bactericidal effect against Typhi. Although Vi-CPS is a reliable vaccine, sometimes depolymerization during purification can affect its potency, which can be resolved through a potency test. As the passive haemagglutination test recommended by the World Health Organization does not indicate vaccine potency, we recommend using an SBA to evaluate the bactericidal ability of Vi-CPS.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.047159-0
2013-02-01
2020-08-03
Loading full text...

Full text loading...

/deliver/fulltext/jmm/62/2/283.html?itemId=/content/journal/jmm/10.1099/jmm.0.047159-0&mimeType=html&fmt=ahah

References

  1. Acharya I. L., Lowe C. U., Thapa R., Gurubacharya V. L., Shrestha M. B., Cadoz M., Schulz D., Armand J., Bryla D. A. other authors 1987; Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella Typhi. A preliminary report. N Engl J Med 317:1101–1104 [CrossRef][PubMed]
    [Google Scholar]
  2. Ahmadi H., Tabaraie B., Nejati M., Al-e-Agha S. 1999; Molecular characterization and optimization of Vi-capsular polysaccharide of Salmonella Typhi Ty6s production in bioreactor. Med J Islam Repub Iran 13:37–42
    [Google Scholar]
  3. Canh D. G., Lin F. Y., Thiem V. D., Trach D. D., Trong N. D., Mao N. D., Hunt S., Schneerson R., Robbins J. B. other authors 2004; Effect of dosage on immunogenicity of a Vi conjugate vaccine injected twice into 2- to 5-year-old Vietnamese children. Infect Immun 72:6586–6588 [CrossRef][PubMed]
    [Google Scholar]
  4. Chibber S., Bhardwaj S. B. 2004; Protection in a mouse peritonitis model mediated by iron-regulated outer-membrane protein of Salmonella typhi coupled to its Vi antigen. J Med Microbiol 53:705–709 [CrossRef][PubMed]
    [Google Scholar]
  5. Fadeel M. A., Crump J. A., Mahoney F. J., Nakhla I. A., Mansour A. M., Reyad B., El Melegi D., Sultan Y., Mintz E. D., Bibb W. F. 2004; Rapid diagnosis of typhoid fever by enzyme-linked immunosorbent assay detection of Salmonella serotype Typhi antigens in urine. Am J Trop Med Hyg 70:323–328[PubMed]
    [Google Scholar]
  6. Frantz I. D. 1942; Growth requirements of the Meningococcus . J Bacteriol 43:757–761[PubMed]
    [Google Scholar]
  7. Gotschlich E. C. 1975; Development of polysaccharide vaccines for the prevention of meningococcal diseases. Monogr Allergy 9:245–258[PubMed]
    [Google Scholar]
  8. Hestrin S. 1949; The reaction of acetylcholine and other carboxylic acid derivatives with hydroxylamine, and its analytical application. J Biol Chem 180:249–261[PubMed]
    [Google Scholar]
  9. Holst J., Feiring B., Fuglesang J. E., Høiby E. A., Nøkleby H., Aaberge I. S., Rosenqvist E. 2003; Serum bactericidal activity correlates with the vaccine efficacy of outer membrane vesicle vaccines against Neisseria meningitidis serogroup B disease. Vaccine 21:734–737 [CrossRef][PubMed]
    [Google Scholar]
  10. Hudson L., Hay F. 1989 Practical Immunology, 3rd edn. Oxford: Blackwell Scientific Publishers;
    [Google Scholar]
  11. Kasi A. M. 1964; Physical and chemical studies of two dried inactivated typhoid vaccines (Vaccines K and L). Bull World Health Organ 30:647–652[PubMed]
    [Google Scholar]
  12. Kim Y.-R., Yoo J. H., Hur J. K., Kang J. H., Shin W. S., Kang M. W. 1995; Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea. J Korean Med Sci 10:314–317[PubMed] [CrossRef]
    [Google Scholar]
  13. Klugman K., Koornhof H. J., Schneerson R., Cadoz M., Gilbertson I. T., Robbins J. B., Schulz D., Armand J. 1987; Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet U 330:1165–1169 [CrossRef]
    [Google Scholar]
  14. Klugman K. P., Koornhof H. J., Robbins J. B., Le Cam N. N. 1996; Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14:435–438 [CrossRef][PubMed]
    [Google Scholar]
  15. Lim S. M., Jung H.-S., Kim M. J., Park D.-W., Kim W.-J., Cheong H.-J., Park S.-C., Lee K.-C., Shin Y.- K. other authors 2007; Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea. J Microbiol Biotechnol 17:611–615[PubMed]
    [Google Scholar]
  16. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J. 1951; Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275[PubMed]
    [Google Scholar]
  17. Maslanka S. E., Gheesling L. L., Libutti D. E., Donaldson K. B., Harakeh H. S., Dykes J. K., Arhin F. F., Devi S. J., Frasch C. E. other authors 1997; Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. Clin Diagn Lab Immunol 4:156–167[PubMed]
    [Google Scholar]
  18. Mastroeni P., Ménager N. 2003; Development of acquired immunity to Salmonella . J Med Microbiol 52:453–459 [CrossRef][PubMed]
    [Google Scholar]
  19. Nolan C. M., Feeley J. C., White P. C. Jr, Hambie E. A., Brown S. L., Wong K.-H. 1980; Evaluation of a new assay for Vi antibody in chronic carriers of Salmonella typhi . J Clin Microbiol 12:22–26[PubMed]
    [Google Scholar]
  20. Rodríguez T., Lastre M., Cedré B., del Campo J., Bracho G., Zayas C., Taboada C., Díaz M., Sierra G., Pérez O. 2002; Standardization of Neisseria meningitidis serogroup B colorimetric serum bactericidal assay. Clin Diagn Lab Immunol 9:109–114[PubMed]
    [Google Scholar]
  21. Szu S. C., Li X.-R., Stone A. L., Robbins J. B. 1991; Relation between structure and immunologic properties of the Vi capsular polysaccharide. Infect Immun 59:4555–4561[PubMed]
    [Google Scholar]
  22. Szu S. C., Taylor D. N., Trofa A. C., Clements J. D., Shiloach J., Sadoff J. C., Bryla D. A., Robbins J. B. 1994; Laboratory and preliminary clinical characterization of Vi capsular polysaccharide–protein conjugate vaccines. Infect Immun 62:4440–4444[PubMed]
    [Google Scholar]
  23. Tang S.-S., Tan W.-S., Devi S., Wang L.-F., Pang T., Thong K.-L. 2003; Mimotopes of the Vi antigen of Salmonella enterica serovar Typhi identified from phage display peptide library. Clin Diagn Lab Immunol 10:1078–1084[PubMed]
    [Google Scholar]
  24. Wain J., House D., Zafar A., Baker S., Nair S., Kidgell C., Bhutta Z., Dougan G., Hasan R. 2005; Vi antigen expression in Salmonella enterica serovar Typhi clinical isolates from Pakistan. J Clin Microbiol 43:1158–1165 [CrossRef][PubMed]
    [Google Scholar]
  25. WHO 1973; General Requirements for the Sterility of Biological Substances; 25th report. WHO Technical Report Series, No. 530. Geneva: World Health Organization; Annex 4
  26. WHO 1974; Requirements for Vi-polysaccharide Typhoid Vaccine. WHO Technical Report. Series, No. 840. Geneva: World Health Organization; Annex 1
  27. WHO 1976; Requirements for Meningococcal Polysaccharide Vaccine; 27th report. WHO Technical Report Series, No. 594. Geneva: World Health Organization; Annex 2
  28. WHO 1979; The International Pharmacopoeia, 3rd edn, Vol. 1. General Methods of Analysis . Geneva: World Health Organization;
  29. WHO 1981; Requirements for meningococcal polysaccharide vaccine (Requirements for biological substances no. 23, addendum 1980). In: WHO Expert Committee on Biological Standardization 31st report. WHO Technical Report Series, No. 658. Geneva: World Health Organization. Annex 6
    [Google Scholar]
  30. WHO 1994; Requirements for Vi Polysaccharide Typhoid Vaccine. WHO Technical Report Series, No. 840. Geneva: World Health Organization; Annex 1
  31. Yang H. H., Wu C. G., Xie G. Z., Gu Q. W., Wang B. R., Wang L. Y., Wang H. F., Ding Z. S., Yang Y. other authors 2001; Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 79:625–631[PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.047159-0
Loading
/content/journal/jmm/10.1099/jmm.0.047159-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error